Tim Bongartz

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
  2. pmc Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al
    Eric L Matteson
    Arthritis Res Ther 8:404. 2006
  3. ncbi Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study
    T Bongartz
    Department of Internal Medicine I, University of Regensburg, Germany
    Rheumatology (Oxford) 44:126-9. 2005
  4. ncbi Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease?
    Tim Bongartz
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Clin Pract Rheumatol 1:80-1. 2005
  5. ncbi Citrullination in extra-articular manifestations of rheumatoid arthritis
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, 200 1St St SW Rochester, MN 55905, USA
    Rheumatology (Oxford) 46:70-5. 2007
  6. ncbi Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Tim Bongartz
    Division of Rheumatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 295:2275-85. 2006
  7. doi Tocilizumab for rheumatoid and juvenile idiopathic arthritis
    Tim Bongartz
    Department of Internal Medicine and Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 371:961-3. 2008
  8. doi Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Ann Rheum Dis 68:1177-83. 2009
  9. doi Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis
    Tim Bongartz
    Mayo Clinic College of Medicine, Division of Rheumatology, Rochester, Minnesota 55905, USA
    Arthritis Rheum 59:1713-20. 2008
  10. doi Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study
    Tim Bongartz
    Rheumatology Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 62:1583-91. 2010

Collaborators

Detail Information

Publications24

  1. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  2. pmc Response to commentary by Dixon and Silman on the systematic review and meta-analysis by Bongartz et al
    Eric L Matteson
    Arthritis Res Ther 8:404. 2006
  3. ncbi Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study
    T Bongartz
    Department of Internal Medicine I, University of Regensburg, Germany
    Rheumatology (Oxford) 44:126-9. 2005
    ..Therefore, we studied the use of pioglitazone, a PPARgamma agonist originally developed for the treatment of diabetes, in patients with PsA...
  4. ncbi Is tacrolimus effective for treating antisynthetase-associated interstitial lung disease?
    Tim Bongartz
    Division of Rheumatology, Mayo Clinic, Rochester, MN 55905, USA
    Nat Clin Pract Rheumatol 1:80-1. 2005
  5. ncbi Citrullination in extra-articular manifestations of rheumatoid arthritis
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, 200 1St St SW Rochester, MN 55905, USA
    Rheumatology (Oxford) 46:70-5. 2007
    ..We therefore investigated the presence of citrullination in two extra-articular manifestations of RA, interstitial pneumonia (IP) and rheumatoid nodules...
  6. ncbi Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    Tim Bongartz
    Division of Rheumatology and Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    JAMA 295:2275-85. 2006
    ..Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies...
  7. doi Tocilizumab for rheumatoid and juvenile idiopathic arthritis
    Tim Bongartz
    Department of Internal Medicine and Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Lancet 371:961-3. 2008
  8. doi Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
    T Bongartz
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Ann Rheum Dis 68:1177-83. 2009
    ..To assess the risk of malignancy with etanercept, a fusion protein that inhibits TNF action, a meta-analysis was performed using individual patient data from randomised controlled trials (RCT) in patients with rheumatoid arthritis (RA)...
  9. doi Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis
    Tim Bongartz
    Mayo Clinic College of Medicine, Division of Rheumatology, Rochester, Minnesota 55905, USA
    Arthritis Rheum 59:1713-20. 2008
    ..We conducted a study to evaluate potential risk factors of prosthetic joint infection and to clarify if RA is an independent predictor of this complication...
  10. doi Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study
    Tim Bongartz
    Rheumatology Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 62:1583-91. 2010
    ..Interstitial lung disease (ILD) has been recognized as an important comorbidity in rheumatoid arthritis (RA). We undertook the current study to assess incidence, predictors, and mortality of RA-associated ILD...
  11. ncbi Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab
    T Bongartz
    University of Regensburg, Regensburg, Germany
    Arthritis Rheum 52:280-2. 2005
    ..Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP...
  12. doi Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study
    Carlotta Nannini
    Mayo Clinic College of Medicine, Rochester, Minnesota
    Arthritis Care Res (Hoboken) 65:1243-50. 2013
    ..We therefore aimed to assess the incidence, risk factors, and mortality of OLD in patients with RA...
  13. ncbi Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia
    Sarah R Atkins
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Arthritis Rheum 54:635-41. 2006
    ..We performed a morphologic and quantitative analysis of B lymphocytes and plasma cells in RA-associated interstitial pneumonia (IP) in comparison with idiopathic IP and normal lungs...
  14. pmc Incidence of spondyloarthropathy in patients with Crohn's disease: a population-based study
    Raina Shivashankar
    Department of Medicine, Division of Gastroenterology and Hepatology and Division of Rheumatology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Rheumatol 39:2148-52. 2012
    ..We assessed the cumulative incidence and clinical spectrum of SpA in patients with Crohn's disease (CD) in a population-based cohort...
  15. pmc Histoplasmosis infection in patients with rheumatoid arthritis, 1998-2009
    Timothy C Olson
    Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    BMC Infect Dis 11:145. 2011
    ..Patients with rheumatic diseases including rheumatoid arthritis (RA) are at increased risk for infections related to both the disease and its treatments. These include uncommonly reported infections due to histoplasmosis...
  16. pmc Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia
    S R Atkins
    Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Ann Rheum Dis 65:677-80. 2006
    ..The role of mast cells in extra-articular manifestations of rheumatoid arthritis (RA) has not been studied so far...
  17. doi Perioperative care for patients with rheumatic diseases
    Bharath M Akkara Veetil
    Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    Nat Rev Rheumatol 8:32-41. 2012
    ....
  18. ncbi Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach
    P Harle
    Laboratory of Neuroendocrinoimmunology, Department of Internal Medicine I, University Hospital, Regensburg, Germany
    Rheumatology (Oxford) 44:426-33. 2005
    ..Therefore, this review focuses on the multidisciplinary aspects of neuroendocrine-immune changes in RA...
  19. ncbi Citrullinated proteins in rheumatoid arthritis: crucial...but not sufficient!
    Tineke Cantaert
    University of Amsterdam, Amsterdam, The Netherlands
    Arthritis Rheum 54:3381-9. 2006
  20. ncbi CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis
    Joshua J Michel
    Children s Hospital of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    Arthritis Rheum 56:43-57. 2007
    ..T cells deficient in CD28 expression have been implicated in the pathogenesis of rheumatoid arthritis (RA). Given that CD28-null T cells are functionally heterogeneous, we undertook this study to screen for novel receptors on these cells...
  21. ncbi Tumor necrosis factor antagonists and infections: the small print on the price tag
    Tim Bongartz
    Arthritis Rheum 53:631-5. 2005
  22. doi Malignancy and biologic therapy in rheumatoid arthritis
    Johan Askling
    Department of Medicine, Clinical Epidemiology Unit, Karolinska University Hospital and Karolinska Institute, Sweden
    Curr Opin Rheumatol 20:334-9. 2008
    ....
  23. ncbi Elective orthopedic surgery and perioperative DMARD management: many questions, fewer answers, and some opinions
    Tim Bongartz
    J Rheumatol 34:653-5. 2007
  24. ncbi Interstitial lung disease in connective tissue diseases: what are the important questions?
    Jay H Ryu
    Arthritis Rheum 53:488-90. 2005